Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
105
Completed, industry sponsors, Endocrinology and women's health, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed105
105 trials
Showing 1 to 25, recently updated first.
AmgenAmgen (AMGN)
NCT06079476 · 100 participants · Start Oct 30, 2023 · Primary completion Oct 18, 2025
Drug: Romosozumab · For: Postmenopausal Osteoporosis
Sites: Ahmedabad, India; Bangalore, India; Mumbai, India · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05631795 · 40 participants · Start Aug 9, 2022 · Primary completion Jun 12, 2025
Drug: Alpelisib; Fulvestrant · For: Advanced Breast Cancer
Sites: Guwahati, India; Surat, India; Thalassery, India · 12 sites in all
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis WomenCompleted
Dong-A ST Co., Ltd.Industry
NCT05630768 · 149 participants · Start Jan 3, 2023 · Primary completion Jul 23, 2025
Drug: Risedronate Sodium 35 MG [Actonel]; Calcium Vitamin D combination · For: Postmenopausal Osteoporosis
Sites: Seoul, South Korea
- Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)Pivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT05772169 · 1,113 participants · Start Mar 31, 2023 · Primary completion Nov 19, 2024
Drug: Mifepristone 300 MG [Korlym]; Placebo for mifepristone · For: Hypercortisolism; Diabetes Mellitus, Type 2
Sites: Escondido, California; Gardena, California; Huntington Park, California · 36 sites in all
RECORDATI GROUPIndustry
NCT01794793 · 337 participants · Start Jun 10, 2013 · Primary completion Jul 25, 2023
Drug: Pasireotide; Cabergoline and 1 more · For: Cushing's Disease; Acromegaly; Neuroendocrine Tumors and 6 more
Sites: La Jolla, California; Los Angeles, California; Stanford, California · 94 sites in all
- A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01350934 · 219 participants · Start Jun 19, 2011 · Primary completion Jan 10, 2013
Drug: alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus); Calcitriol · For: Osteoporosis, Postmenopausal
- Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00729651 · 343 participants · Start Mar 20, 2008 · Primary completion Apr 10, 2009
Drug: alendronate sodium (+) cholecalciferol; Comparator: Alendronate sodium (Fosamax) · For: Osteoporosis Postmenopausal
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01562834 · 22 participants · Start Oct 21, 1998 · Primary completion Dec 1, 2002
Drug: somatropin; placebo · For: Growth Hormone Disorder; Adult Growth Hormone Deficiency
Sites: Angers, France; Boisguillaume, France; Brest, France · 24 sites in all
- Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal AtrophyPivotal-lookingCompleted
ASCEND TherapeuticsIndustry
NCT00160173 · 221 participants · Start Dec 2, 2004 · Primary completion Sep 6, 2005
Drug: Estrogel · For: Postmenopausal Symptoms
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 109 sites in all
PfizerPfizer (PFE)
NCT02679755 · 252 participants · Start Mar 9, 2016 · Primary completion Jul 25, 2019
Drug: Palbociclib; Letrozole · For: Breast Cancer
Sites: North Sydney, Australia; St Leonards, Australia; Auchenflower, Australia · 34 sites in all
IBSA Institut Biochimique SAIndustry
NCT03094416 · 66 participants · Start Jul 30, 2018 · Primary completion Jun 15, 2020
Drug: levothyroxine sodium capsule; Proton pump inhibitor (PPI) and 1 more · For: Hypothyroidism;Postablative
Sites: La Jolla, California; Ventura, California; Washington D.C., District of Columbia · 9 sites in all
- Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00431093 · 570 participants · Start Nov 2002 · Primary completion Mar 2005
Drug: tibolone; low-dose estradiol/noresterone · For: Menopause
Novartis PharmaceuticalsNovartis (NVS)
NCT00688909 · 261 participants · Start Mar 2008 · Primary completion Jun 2009
Drug: letrozole · For: Breast Cancer
Sites: Huntsville, Alabama; Little Rock, Arkansas; Grass Valley, California · 48 sites in all
Lantheus Medical ImagingIndustry
NCT00162370 · 400 participants · Start Apr 2004 · Primary completion Sep 2012
Drug: Perflutren Lipid Microsphere Injectable Suspension · For: Coronary Artery Disease; Heart Disease
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01732770 · 643 participants · Start Nov 7, 2012 · Primary completion Jan 7, 2015
Drug: Denosumab; Zoledronic Acid and 2 more · For: Post Menopausal Osteoporosis
Sites: Santa Monica, California; Lakewood, Colorado; Longmont, Colorado · 45 sites in all
- A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip FracturePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00887354 · 224 participants · Start Apr 2009 · Primary completion Aug 2015
Drug: Teriparatide; Risedronate and 1 more · For: Osteoporosis
Sites: Fort Lauderdale, Florida; New Port Richey, Florida; Orlando, Florida · 28 sites in all
- VERtebral Fracture Treatment Comparisons in Osteoporotic WomenPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01709110 · 1,366 participants · Start Oct 2012 · Primary completion Jul 2016
Drug: Teriparatide; Risedronate and 3 more · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Concord, California; Fresno, California · 103 sites in all
IpsenIndustry
NCT00216398 · 8 participants · Start Jun 2004 · Primary completion Jun 22, 2006
Drug: Lanreotide (Autogel formulation) · For: Acromegaly
Sites: Westmead, Australia
- Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With OsteoporosisPivotal-lookingCompleted
Hanlim Pharm. Co., Ltd.Industry
NCT01675297 · 1,053 participants · Start Jul 4, 2011 · Primary completion Dec 2013
Drug: Risedronate/Cholecalciferol combination; Risedronate · For: Osteoporosis
Sites: Seoul, South Korea
IpsenIndustry
NCT00149188 · 30 participants · Start Feb 2004 · Primary completion Aug 24, 2005
Drug: Lanreotide (Autogel formulation) · For: Acromegaly
Sites: Hull, United Kingdom; Hampstead, United Kingdom; Aberdeen, United Kingdom · 10 sites in all
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02060383 · 249 participants · Start May 23, 2014 · Primary completion Feb 5, 2018
Drug: Pasireotide s.c.; Sitagliptin and 4 more · For: Cushing's Disease; Acromegaly
Sites: Multiple Locations, California; Torrance, California; Ventura, California · 43 sites in all
IpsenIndustry
NCT00701363 · 124 participants · Start Oct 2008 · Primary completion Mar 2013
Drug: Lanreotide Autogel 120 mg · For: Acromegaly
Sites: Rio de Janeiro, Brazil; São Paulo, Brazil; Arhus C, Denmark · 44 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT02311894 · 82 participants · Start Mar 31, 2015 · Primary completion Nov 8, 2017
Drug: Somatropin · For: Growth Hormone Deficiency
Sites: Little Rock, Arkansas; Orange, California; Sacramento, California · 33 sites in all
LG Life SciencesIndustry
NCT03015909 · 116 participants · Start Aug 11, 2016 · Primary completion Dec 21, 2017
Drug: Somatropin · For: Short Stature, Idiopathic; Infant, Small for Gestational Age; Growth Hormone Deficiency and 2 more
Sites: Suwon, South Korea
- The Effect of Vitamin K2 on Bone TurnoverPivotal-lookingCompleted
Eisai LimitedEisai
NCT00548509 · 131 participants · Start Feb 1, 2002 · Primary completion Jan 2013
Drug: Menatetrenone (Vitamin K2) · For: Osteoporosis
Sites: Kumagaya-shi, Japan; Hachioji-shi, Japan; Setagaya-Ku, Japan · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.